Sanofi's Rilzabrutinib gets US Orphan Drug status for sickle cell
Ticker: SNYNF · Form: 6-K · Filed: Jun 6, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Jun 6, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: orphan-drug-designation, FDA, sickle-cell-disease, drug-development
TL;DR
Sanofi's Rilzabrutinib just got FDA Orphan Drug status for sickle cell - big win for rare disease drug development.
AI Summary
On June 3, 2025, Sanofi announced that its drug Rilzabrutinib received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of sickle cell disease. This designation is significant for rare disease treatments and may provide incentives for further development.
Why It Matters
Orphan Drug Designation can accelerate the development and review process for treatments targeting rare diseases like sickle cell disease, potentially bringing new therapies to patients faster.
Risk Assessment
Risk Level: low — This filing is an informational report of a press release and does not contain material financial changes or strategic shifts that would inherently increase risk.
Key Players & Entities
- Sanofi (company) — Registrant and developer of Rilzabrutinib
- Rilzabrutinib (drug) — Drug that received Orphan Drug Designation
- U.S. Food and Drug Administration (FDA) (company) — Regulatory body that granted the designation
- sickle cell disease (disease) — Indication for which Rilzabrutinib received designation
- June 3, 2025 (date) — Date of the press release
FAQ
What is Rilzabrutinib?
Rilzabrutinib is a drug developed by Sanofi that has received Orphan Drug Designation for the treatment of sickle cell disease.
What is Orphan Drug Designation?
Orphan Drug Designation is a status granted by the FDA to drugs intended to treat rare diseases, offering incentives for development.
When was the press release regarding Rilzabrutinib published?
The press release was published on June 3, 2025.
What is the primary indication for Rilzabrutinib mentioned in this filing?
The primary indication mentioned is sickle cell disease.
Which regulatory body granted the Orphan Drug Designation?
The U.S. Food and Drug Administration (FDA) granted the Orphan Drug Designation.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 6, 2025 regarding Sanofi (SNYNF).